HomeApproved Therapies

Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Santhera Announces Approval in Hong Kong for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
|
Less than 1 min read
|
Updated:

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment.

Santhera Pharmaceuticals announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged 4 years and older.

Read More

- Follow Us -
DMDWarrioR Instagram
Author: Can Ekinci
Add DMDWarrior as a preferred Google source to see more of our trusted coverage.

Disclaimer: No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

DMDWarrior Clinical Trials Hub now available in 10 languages, providing AI-assisted Duchenne clinical trial information worldwide.

Trending on DMDWarrioR- Duchenne News

Load more

Related Articles

Load more